Cliff Asness's ANIP Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 18,842 shares of ANI Pharmaceuticals, Inc. (ANIP) worth $1.45 M, representing 0.00% of the portfolio. First purchased in 2014-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ANIP, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2020, adding 52,740 shares. Largest reduction occurred in Q1 2015, reducing 64,100 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's ANI Pharmaceuticals (ANIP) Holding Value Over Time
Track share changes against reported price movement
Quarterly ANI Pharmaceuticals (ANIP) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +4,876 | Add 34.91% | 18,842 | $76.90 |
| Q4 2025 | -514 | Reduce 3.55% | 13,966 | $78.94 |
| Q3 2025 | -4,121 | Reduce 22.15% | 14,480 | $91.60 |
| Q2 2025 | +4,535 | Add 32.24% | 18,601 | $65.25 |
| Q1 2025 | -2,027 | Reduce 12.60% | 14,066 | $66.95 |
| Q4 2024 | +689 | Add 4.47% | 16,093 | $55.28 |
| Q3 2024 | -2,123 | Reduce 12.11% | 15,404 | $59.66 |
| Q2 2024 | +5,419 | Add 44.76% | 17,527 | $63.68 |
| Q1 2024 | +7,527 | Add 164.31% | 12,108 | $69.13 |
| Q4 2023 | +4,581 | New Buy | 4,581 | $55.14 |
| Q2 2022 | -28,738 | Sold Out | 0 | $0.00 |
| Q1 2022 | +21,058 | Add 274.19% | 28,738 | $28.12 |
| Q4 2021 | +7,680 | New Buy | 7,680 | $46.09 |
| Q3 2021 | -19,542 | Sold Out | 0 | $0.00 |
| Q2 2021 | -1,274 | Reduce 6.12% | 19,542 | $35.05 |
| Q1 2021 | -13,424 | Reduce 39.21% | 20,816 | $36.13 |
| Q4 2020 | -4,095 | Reduce 10.68% | 34,240 | $29.03 |
| Q3 2020 | -16,831 | Reduce 30.51% | 38,335 | $28.20 |
| Q2 2020 | -5,246 | Reduce 8.68% | 55,166 | $32.34 |
| Q1 2020 | +52,740 | Add 687.43% | 60,412 | $40.74 |
| Q4 2019 | +3,014 | Add 64.71% | 7,672 | $61.65 |
| Q3 2019 | -1,961 | Reduce 29.63% | 4,658 | $72.78 |
| Q2 2019 | -1,464 | Reduce 18.11% | 6,619 | $82.19 |
| Q1 2019 | +843 | Add 11.64% | 8,083 | $70.52 |
| Q4 2018 | -2,552 | Reduce 26.06% | 7,240 | $45.03 |
| Q3 2018 | +1,757 | Add 21.87% | 9,792 | $56.58 |
| Q2 2018 | -1,773 | Reduce 18.08% | 8,035 | $66.83 |
| Q1 2018 | +9,808 | New Buy | 9,808 | $58.22 |
| Q3 2017 | -5,264 | Sold Out | 0 | $0.00 |
| Q2 2017 | -32 | Reduce 0.60% | 5,264 | $46.73 |
| Q1 2017 | +1,144 | Add 27.55% | 5,296 | $49.47 |
| Q4 2016 | +4,152 | New Buy | 4,152 | $60.69 |
| Q3 2016 | -12,126 | Sold Out | 0 | $0.00 |
| Q2 2016 | +1,558 | Add 14.74% | 12,126 | $55.83 |
| Q1 2016 | -2,120 | Reduce 16.71% | 10,568 | $33.69 |
| Q4 2015 | -7,141 | Reduce 36.01% | 12,688 | $45.16 |
| Q3 2015 | -16,195 | Reduce 44.96% | 19,829 | $39.49 |
| Q2 2015 | -6,781 | Reduce 15.84% | 36,024 | $62.07 |
| Q1 2015 | -64,100 | Reduce 59.96% | 42,805 | $62.56 |
| Q4 2014 | +12,505 | Add 13.25% | 106,905 | $56.40 |
| Q3 2014 | +94,400 | New Buy | 94,400 | $28.28 |
Cliff Asness's ANI Pharmaceuticals Investment FAQs
Cliff Asness first purchased ANI Pharmaceuticals, Inc. (ANIP) in Q3 2014, acquiring 94,400 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held ANI Pharmaceuticals, Inc. (ANIP) for 41 quarters since Q3 2014.
Cliff Asness's largest addition to ANI Pharmaceuticals, Inc. (ANIP) was in Q3 2014, adding 94,400 shares worth $2.67 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 18,842 shares of ANI Pharmaceuticals, Inc. (ANIP), valued at approximately $1.45 M.
As of the Q1 2026 filing, ANI Pharmaceuticals, Inc. (ANIP) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in ANI Pharmaceuticals, Inc. (ANIP) was 106,905 shares, as reported at the end of Q4 2014.